Alimentiv and International Bowel Ultrasound Group Collaborate on Clinical Ultrasound Training

Expanding Clinical Training in Ultrasound

In a significant move to enhance clinical trials focused on gastroenterology, Alimentiv Inc., a global leader in clinical research, has strengthened its partnership with the International Bowel Ultrasound Group (IBUS). This collaboration aims to advance the utilization of intestinal ultrasound in clinical research, a crucial development for improving patient outcomes in the realm of inflammatory bowel disease (IBD).

On October 16, 2026, the two organizations announced the launch of the IUS-STAR (IUS Standardized Training and Acquisition for Research) program. This structured and scalable training initiative is designed for professionals operating within clinical trials, including sonographers, radiologists, and technicians. The focus of IUS-STAR is to provide advanced and accelerated training in intestinal ultrasound (IUS), facilitating the preparations of research centers and broadening access to qualified personnel globally.

The Significance of Intestinal Ultrasound

The collaborative effort is vital because it seeks to enhance the clinical imaging capabilities used in trials, especially for detecting and monitoring IBD. According to Stephanie Gonzalez, Chief Operating Officer of Alimentiv, “IUS-STAR leverages the scientific expertise of IBUS along with our operational infrastructure. This partnership translates to faster startup times for clinical centers and an increase in the number of sites prepared to use IUS within IBD clinical trials.”

This initiative comes in light of the considerable progress Alimentiv and IBUS have made since their joint venture started in 2022. Together, they have successfully integrated IUS into clinical practices across more than 34 countries. The focus has been on standardizing and implementing this non-invasive imaging modality, enhancing its role as an essential tool in ongoing IBD investigations.

What the IUS-STAR Program Offers

The IUS-STAR program features a well-structured curriculum combining optimized online training with practical imaging acquisition and iterative reviews of captured images. This approach ensures that participants receive dedicated feedback and support, enhancing their skills and confidence in producing high-quality images that adhere to clinical trial protocols.

Kerri Novak, Director-General of IBUS, noted the substantial impact of utilizing intestinal ultrasound. “This reproducible and well-tolerated tool allows for comprehensive evaluation of the bowel in clinical trials. It not only enhances the identification of patients with active disease but also increases patient accessibility in clinical research.”

Commitment to Ongoing Innovation

Alimentiv and IBUS are deeply committed to fostering training, standardization, and innovation in the field of intestinal ultrasound. These efforts ultimately benefit researchers, study centers, sponsors, and patients living with gastrointestinal diseases. With a growing interest in non-invasive disease monitoring, the IUS-STAR program stands as a pivotal resource in advancing clinical trial efficacy and patient care.

For those interested in learning more about the IUS-STAR initiative, detailed information can be obtained by reaching out via the provided contact email.

Conclusion

As Alimentiv continues to lead in gastrointestinal research and clinical trials, their collaboration with IBUS represents a progressive step towards enhancing the quality and reach of clinical imaging in gastrointestinal diseases. The IUS-STAR program exemplifies the importance of structured training in ensuring that healthcare professionals are well-equipped to handle advancements in diagnostic imaging, ultimately leading to better clinical outcomes for patients suffering from inflammatory bowel conditions.

For additional insights on Alimentiv's work, visit alimentiv.com for comprehensive details about their global initiatives and offerings.